{
    "root": "e268a1a4-8598-4baa-9ff9-62ad5cab5968",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Dabigatran Etexilate",
    "value": "20241031",
    "ingredients": [
        {
            "name": "DABIGATRAN ETEXILATE MESYLATE",
            "code": "SC7NUW5IIT"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "FUMARIC ACID",
            "code": "88XHZ13131"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        }
    ],
    "indications": "dabigatran etexilate capsules direct thrombin inhibitor indicated : \u2022 reduce risk stroke systemic embolism adult patients non-valvular atrial fibrillation ( 1.1 ) \u2022 treatment deep venous thrombosis ( dvt ) pulmonary embolism ( pe ) adult patients treated parenteral anticoagulant 5-10 days ( 1.2 ) \u2022 reduce risk recurrence dvt pe adult patients previously treated ( 1.3 ) \u2022 prophylaxis dvt pe adult patients undergone hip replacement surgery ( 1.4 ) \u2022 treatment venous thromboembolic events ( vte ) pediatric patients 8 less 18 years age treated parenteral anticoagulant least 5 days ( 1.5 ) \u2022 reduce risk recurrence vte pediatric patients 8 less 18 years age previously treated ( 1.6 )",
    "contraindications": "\u2022 non-valvular atrial fibrillation adult patients : patients crcl > 30 ml/min : 150 mg orally , twice daily ( 2.2 ) patients crcl 15-30 ml/min : 75 mg orally , twice daily ( 2.2 ) \u2022 treatment dvt pe adult patients : patients crcl > 30 ml/min : 150 mg orally , twice daily 5-10 days parenteral anticoagulation ( 2.2 ) \u2022 reduction risk recurrence dvt pe adult patients : patients crcl > 30 ml/min : 150 mg orally , twice daily previous treatment ( 2.2 ) \u2022 prophylaxis dvt pe following hip replacement surgery adult patients : patients crcl > 30 ml/min : 110 mg orally first day , 220 mg daily ( 2.2 ) \u2022 treatment pediatric vte : pediatric patients : weight-based , twice daily least 5 days parenteral anticoagulant ( 2.3 ) \u2022 reduction risk recurrence pediatric vte : pediatric patients : weight-based , twice daily previous treatment ( 2.3 ) \u2022 dabigatran etexilate capsules substitutable milligram-to-milligram basis dabigatran etexilate forms \u2022 review recommendations converting oral parenteral anticoagulants ( 2.6 , 2.7 ) \u2022 temporarily discontinue dabigatran etexilate capsules invasive surgical procedures possible , restart promptly ( 2.8 )",
    "warningsAndPrecautions": "dabigatran etexilate capsules available containing 86.48 mg 172.95 mg dabigatran etexilate mesylate equivalent 75 mg 150 mg dabigatran etexilate , respectively . 75 mg capsules hard-shell hypromellose capsules white opaque cap white opaque body filled white off-white powder . capsules axially printed mylan de 75 black ink cap body . available follows : ndc 0378-0265-93bottles 30 capsules ndc 0378-0265-91bottles 60 capsules 150 mg capsules hard-shell hypromellose capsules light purple opaque cap white opaque body filled white off-white powder . capsules axially printed mylan de 150 black ink cap body . available follows : ndc 0378-0266-93bottles 30 capsules ndc 0378-0266-91bottles 60 capsules store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) . [ usp controlled room temperature . ] opened , product must used within 4 months . keep bottle tightly closed . store original package protect moisture . pharmacist : dispense medication guide prescription .",
    "adverseReactions": "dabigatran etexilate capsules contraindicated patients : \u2022active pathological bleeding [ ( 5.2 ) ( 6.1 ) ] \u2022history serious hypersensitivity reaction dabigatran , dabigatran etexilate , one excipients product ( e.g . , anaphylactic reaction anaphylactic shock ) [ ( 6.1 ) ] \u2022mechanical prosthetic heart valve [ ( 5.4 ) ]",
    "indications_original": "Dabigatran etexilate capsules are a direct thrombin inhibitor indicated: \u2022 To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.1 ) \u2022 For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in adult patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) \u2022 To reduce the risk of recurrence of DVT and PE in adult patients who have been previously treated ( 1.3 ) \u2022 For the prophylaxis of DVT and PE in adult patients who have undergone hip replacement surgery ( 1.4 ) \u2022 For the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.5 ) \u2022 To reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated ( 1.6 )",
    "contraindications_original": "\u2022 Non-valvular Atrial Fibrillation in Adult Patients: o For patients with CrCl > 30 mL/min: 150 mg orally, twice daily ( 2.2 ) o For patients with CrCl 15-30 mL/min: 75 mg orally, twice daily ( 2.2 ) \u2022 Treatment of DVT and PE in Adult Patients: o For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after 5-10 days of parenteral anticoagulation ( 2.2 ) \u2022 Reduction in the Risk of Recurrence of DVT and PE in Adult Patients : o For patients with CrCl > 30 mL/min: 150 mg orally, twice daily after previous treatment ( 2.2 ) \u2022 Prophylaxis of DVT and PE Following Hip Replacement Surgery in Adult Patients : o For patients with CrCl > 30 mL/min: 110 mg orally first day, then 220 mg once daily ( 2.2 ) \u2022 Treatment of Pediatric VTE: o For pediatric patients: weight-based dosage, twice daily after at least 5 days of parenteral anticoagulant ( 2.3 ) \u2022 Reduction in the Risk of Recurrence of Pediatric VTE: o For pediatric patients: weight-based dosage, twice daily after previous treatment ( 2.3 ) \u2022 Dabigatran etexilate capsules are NOT substitutable on a milligram-to-milligram basis with other dabigatran etexilate dosage forms \u2022 Review recommendations for converting to or from other oral or parenteral anticoagulants ( 2.6 , 2.7 ) \u2022 Temporarily discontinue dabigatran etexilate capsules before invasive or surgical procedures when possible, then restart promptly ( 2.8 )",
    "warningsAndPrecautions_original": "Dabigatran Etexilate Capsules are available containing 86.48 mg or 172.95 mg of dabigatran etexilate mesylate equivalent to 75 mg or 150 mg of dabigatran etexilate, respectively.\n                  The 75 mg capsules are hard-shell hypromellose capsules with a white opaque cap and a white opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over DE 75 in black ink on both the cap and body. They are available as follows:\n                  NDC 0378-0265-93bottles of 30 capsules\n                  NDC 0378-0265-91bottles of 60 capsules\n                  The 150 mg capsules are hard-shell hypromellose capsules with a light purple opaque cap and a white opaque body filled with white to off-white powder. The capsules are axially printed with MYLAN over DE 150 in black ink on both the cap and body. They are available as follows:\n                  NDC 0378-0266-93bottles of 30 capsules\n                  NDC 0378-0266-91bottles of 60 capsules\n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F). [See USP Controlled Room Temperature.] Once opened, the product must be used within 4 months. Keep the bottle tightly closed. Store in the original package to protect from moisture.\n                  \n                     PHARMACIST: Dispense a Medication Guide with each prescription.",
    "adverseReactions_original": "Dabigatran etexilate capsules are contraindicated in patients with: \n                  \n                     \n                        \u2022Active pathological bleeding [see Warnings and Precautions (5.2) and Adverse Reactions (6.1)]\n                     \n                     \n                        \u2022History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock) [see Adverse Reactions (6.1)]\n                     \n                     \n                        \u2022Mechanical prosthetic heart valve [see Warnings and Precautions (5.4)]"
}